Clinical Trials in South Korea / NCT05575024
Recruiting
Observational
Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
NCT05575024 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
Acute Kidney Injury Due to Sepsis
Investigational drug(s) / intervention(s)
oXiris membranePolysulfone membrane
oXiris membrane: Perform continuous renal replacement therapy with oXiris membrane
Polysulfone membrane: Perform continuous renal replacement therapy with polysulfone membrane
Study summary
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
Eligibility
Inclusion Criteria:
* Aged ≥ 18 years
* Sepsis related acute kidney injury requiring continuous renal replacement therapy
Exclusion Criteria:
• No monitoring of blood pressure and ECG
Primary outcome measure(s)
- Rate of all-cause mortality — 28 days
Risk of all-cause mortality - Occurrence rates of ventricular tachycardia, intradialytic hypotension — 28 days
Risk of ventricular tachycardia, intradialytic hypotension
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Seoul National University Hospital | Seoul | South Korea | Recruiting |
More Seoul National University Hospital trials in South Korea
Lung Cancer Surgery in Sarcopenia Patients With Old Age
Active, not recruiting
Reduction of Remifentanil-related Complications
Starting soon
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05575024 on ClinicalTrials.gov ↗ ← All trials in South Korea